APA

Thaçi D., Pinter A., Sebastian M., Termeer C., Sticherling M., Gerdes S., Wegner S., Krampe S., Bartz H., Rausch C., Mensch A. & Eyerich K. (20210514). Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). : The British journal of dermatology.

Chicago

Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A and Eyerich K. 20210514. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). : The British journal of dermatology.

Harvard

Thaçi D., Pinter A., Sebastian M., Termeer C., Sticherling M., Gerdes S., Wegner S., Krampe S., Bartz H., Rausch C., Mensch A. and Eyerich K. (20210514). Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). : The British journal of dermatology.

MLA

Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A and Eyerich K. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). : The British journal of dermatology. 20210514.